Clinical Trial Update: A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing once-weekly somapacitan to daily Norditropin in adults previously treated for growth hormone deficiency; trial completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency
• Growth Hormone Disorder

Drugs mentioned

• Norditropin FlexPro (somatropin)
• Somapacitan (somapacitan)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Adult Growth Hormone Deficiency, Growth Hormone Disorder | Phase 3 | Status: COMPLETED | Results posted: 2020-06-16